MedTrace Logo

A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis

NCT00255983 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 491

Last updated 2008-06-03

No results posted yet for this study

Summary

Identifying the role of antibiotics in the treatment of subjects with a microbiologically documented acute exacerbation of chronic bronchitis (AECB) is the purpose of this clinical trial. The trial has been designed to evaluate the efficacy and safety of faropenem medoxomil versus placebo in the treatment of subjects with microbiologically documented AECB.

Conditions

  • Chronic Bronchitis

Interventions

DRUG

Faropenem medoxomil

600 mg BID for 5 days

DRUG

placebo

placebo tablets BID for 5 days

Sponsors & Collaborators

  • INC Research Limited

    collaborator INDUSTRY

  • Replidyne

    lead INDUSTRY

Principal Investigators

  • Roger M Echols, MD · Replidyne, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2008-05-31
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00255983 on ClinicalTrials.gov